QIAGEN N.V.

QGEN Healthcare Diagnostics & Research

QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 7.94%, free cash flow grew 30.5% and total debt rose 13.8%, each against the same quarter a year earlier.

46.13 0.04 −0.09%
Market cap
$9.5B
P/E
23.6×
Fwd P/E
17.5×
Dividend yield
0.76%
F-score
8/9
Altman Z
3.81
Beneish M
−2.60
Dividend safety
66/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

23.07 22.30 20.91 20.03
P/S ratio
4.45 4.67 3.95 3.84
P/FCF ratio
19.48 21.84 20.52 18.31
P/Operating CF
55.78 51.92 82.37 40.20
P/B ratio
2.52 2.59 2.49 2.40
Price to Tangible BV
11.54 14.14 30.90 25.86
EV/Sales
4.66 5.18 4.66 4.25
EV/EBITDA
14.16 16.33 15.31 13.70
EV/Operating CF
14.66 16.54 15.91 13.63
EV/FCF
20.41 24.20 24.24 20.24
Quick Ratio
2.12 2.93 2.18 2.04
Current Ratio
2.60 3.90 3.21 2.85
Net Debt/EBITDA
2.41 3.71 7.34 4.63
Debt/Assets
32.46% 26.34% 28.48% 27.91%
Debt/Equity
0.58 0.44 0.49 0.49
Asset Turnover
0.32 0.35 0.37 0.36
Operating CF/Net income
1.27 1.74 1.48 1.94
Capex/Depreciation
(0.97) (1.42) (0.94) (0.85)
Interest Coverage
15.72 9.81 7.64 13.21
Research and Development Expense of Revenue
9.15% 8.74% 9.80% 9.43%
Selling, General and Administrative Expense of Revenue
26.87% 28.47% 28.92% 27.43%
Intangible Assets out of Total Assets
0.44 0.49 0.53 0.52
Share Based Compensation of Revenue
2.01% 3.07% 1.96% 1.30%
Graham Net Nets
(0.04) (0.05) (0.11) (0.11)
Graham Number
27.78 28.09 26.33 26.73
Earnings Yield
4.34% 4.48% 4.78% 4.99%
Free Cash Flow Yield
5.13% 4.58% 4.87% 5.46%
Revenue per Share
2.59 2.49 2.38 2.59
Operating CF per Share
0.80 0.87 0.49 0.97
Capex per Share
(0.24) (0.33) (0.23) (0.21)
Free Cash Flow per Share
0.56 0.54 0.25 0.76
Cash per Share
8.20 5.06 3.12 3.85
Shareholders Equity per Share
17.71 17.39 16.09 16.27
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
17.71 17.39 16.09 16.27
Free Cash Flow
114.57 116.55 52.15 157.32
Working Capital
1,557.53 1,482.94 1,061.14 1,075.18
Capital Expenditures
(50.45) (71.58) (48.48) (43.37)
Net Current Asset Value
(373.14) (508.00) (910.10) (874.83)
EV/EBIT
19.86 23.23 22.51 20.02
Capex to Sales
0.09 0.13 0.10 0.08
Price to Operating Income
18.96 20.97 19.06 18.11
Other line items
Average Receivables
360.57 375.94 368.66 387.80
Average Payables
76.89 77.96 73.98 80.71
Average Inventory
305.96 290.57 295.49 301.95
Average Assets
6,411.85 5,985.43 5,663.72 5,856.48
Average Common Equity
3,589.70 3,672.75 3,369.79 3,431.62

Fold the line items

Columns are period end dates